Log In
BCIQ
Print this Print this
 

MOB-015

  Manage Alerts
Collapse Summary General Information
Company Moberg Pharma AB
DescriptionTopical formulation of terbinafine
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationOnychomycosis
Indication DetailsTreat onychomycosis
Regulatory Designation
PartnerColep Portugal S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/03/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today